Persephone Biosciences utilizes artificial intelligence and synthetic biology to develop microbial-based immunotherapies that restore human microbiomes, addressing the health impacts of damaged ecosystems. Their approach aims to enhance therapeutic responses and improve patient outcomes in the fight against cancer.
Funding
$15.1M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
+5Founders
Product
Problem
Dysbiosis in human microbial ecosystems can negatively impact health, affecting disease progression, therapeutic response, nutrition, and longevity. Current methods for repairing damaged microbiomes lack the precision and scalability needed for effective treatment.
Solution
Persephone Biosciences is developing microbial-based immunotherapies using synthetic biology and artificial intelligence to restore damaged human microbiomes. The company engineers microbial strains to colonize the gut and modulate the immune system, aiming to improve therapeutic responses, particularly in cancer treatment. By analyzing the composition and function of the microbiome, Persephone identifies key bacterial strains that are missing or dysfunctional in patients. These strains are then optimized through genetic engineering to enhance their therapeutic potential and ensure effective colonization.
Target Audience
The primary target audience includes patients with cancer and other diseases linked to microbiome dysbiosis, as well as infants lacking key bacterial strains for healthy development.
Features
- AI-driven analysis of microbiome composition to identify key bacterial targets
- Synthetic biology platform for engineering and optimizing microbial strains
- Development of microbial-based immunotherapies for cancer and other diseases
- Clinical trials to assess the impact of microbiome modulation on therapeutic outcomes
- Focus on restoring missing or dysfunctional bacteria in the gut
- Technology to ensure engineered bacteria effectively colonize the gut
- "Poop for the Cure" initiative to collect samples and analyze microbiome data from cancer patients
- Development of a supplement containing a set of eight bacteria identified as crucial to infant health